Company intelligence / Profile preview

PureThera

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

PureThera is a South Korean biotechnology company focused on developing next-generation small molecule therapeutics for oncology. The company leverages its proprietary platform to target kinases and metabolic pathways involved in cancer progression and drug resistance. Its lead candidate, PT-101, is a dual AXL/MERTK inhibitor designed to overcome resistance to EGFR inhibitors in non-small cell lung cancer and treat other solid tumors. PureThera aims to address high unmet medical needs through precision medicine and innovative drug discovery.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on PureThera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PureThera.

Explore the full profile